三硝基苯磺酸诱导的C57/BL6小鼠结肠炎模型的建立方法

2,4,6-三硝基苯磺酸(TNBS)诱导的小鼠结肠炎模型是研究人类炎性肠病(inflammatorybowl disease,IBD)的主要手段之一,但在实际应用中,常用的C57/BL品系小鼠却对TNBS有较高耐受性,不易建模.本文主要介绍一种可以有效诱导C57BL6小鼠TNBS结肠炎的方法,并对疾病评价指标进行了具体...     

两种UC小鼠模型的病理损伤和肠道菌群对比研究

目的 用葡聚糖硫酸钠(DSS)和2,4,6-三硝基苯磺酸(TNBS)构建小鼠溃疡性结肠炎模型,对比研究临床症状、结肠组织病理损伤和结肠菌群构成.方法 C57BL/6雄性小鼠30只,随机分为对照组、DSS组和TNBS组.造模期7 d.每日监测临床症状,包括体重和粪便隐血,造模结束时取结肠做组织病理诊断,使用16S rDN...     

4-辛基衣康酸通过激活Nrf2减轻DSS诱导的溃疡性结肠炎

该文主要研究4-辛基衣康酸对葡聚糖硫酸钠(dextran sulfate sodium,DSS)诱导的小鼠溃疡性结肠炎的保护效应.C57BL/6实验小鼠分为空白对照组、衣康酸药物对照组、DSS模型组和衣康酸+DSS干预组.每天观察小鼠体质量、便血情况、粪便性状.PAS染色和TUNEL染色观察小鼠肠黏液分泌和肠上皮细胞凋...     

多次注射乌拉坦诱导的BALB/C及C57BL/6J小鼠肺癌模型的比较

目的探讨一种稳定的多次乌拉坦注射诱导小鼠肺癌模型的构建方法,比较BALB/C及C57BL/6J小鼠对该肺癌模型的敏感性。方法 10只BALB/C小鼠及10只C57BL/6J小鼠适应性饲养3周,随后每只小鼠分别被给予每周1次腹腔注射1 g/kg体重乌拉坦,连续注射10周,继续喂养15周后处死小鼠取肺组织。由3名不同的检测者在解剖显微镜下观察计数肺组织表面肿瘤数目并以直径记录肿瘤大小;HE染色检测肺组织病理变化。结果多次乌拉坦注射诱导的BALB/C及C57BL/6J小鼠肺癌发生率均为10/10(100%);BALB/C小鼠荷瘤数明显多于C57BL/6J小鼠(P0.01),同时,直径也大于C57BL/6J小鼠(P0.05);HE染色显示多次乌拉坦注射诱导的肺癌有非典型性腺瘤增生及腺瘤两种病变类型。结论 BALB/C和C57BL/6J小鼠均可以作为多次注射乌拉坦诱导性肺癌模型的动物,BALB/C小鼠对该肺癌模型的敏感性高于C57BL/6J小鼠。     

黄芩苷对实验性结肠炎小鼠TLRs/MyD88通路的作用研究

本文研究黄芩苷对葡聚糖硫酸钠(DSS)诱导的结肠炎小鼠模型的疗效,并从TLRs/MyD88通路探讨其作用机制。C57BL/6小鼠24只,分为空白对照组、模型组和黄芩苷组,用3.5%DSS诱导结肠炎模型,黄芩苷(30 mg/kg)干预7天,记录小鼠的疾病活动指数(DAI)评分,HE染色观察病理改变并评分,检测结肠髓过氧化物酶(MPO)活性,ELISA法检测肿瘤坏死因子(TNF)-α和白介素(IL)-6浓度,Real-time PCR法检测TLR2、TLR4和MyD88 mRNA表达水平。结果显示黄芩苷能有效抑制结肠炎小鼠DAI评分、结肠组织病理学评分和MPO活性,降低IL-6和TNF-α表达,降低TLR2、TLR4和MyD88 mRNA的表达。表明黄芩苷能有效缓解DSS诱导的结肠炎小鼠模型的症状,降低炎症反应,其作用机制可能是与TLRs/MyD88通路相关。     

不同品系小鼠在三种常见抑郁检测方法中的行为学表现

目的探讨4种不同品系小鼠在3种实验（空场实验、悬尾实验及强迫游泳实验）中的行为学差异,为抗抑郁新药研究中的实验动物选择提供参考。方法利用空场实验检测C57BL/6、BALB/c、ICR、和昆明小鼠的自主活动能力和对新奇环境的探索能力;利用悬尾实验和强迫游泳实验检测它们在应激刺激下的行为绝望状态。结果在空场实验中,BALB/c、ICR和昆明小鼠的运动总路程、运动速度和运动时间明显高于C57BL/6小鼠（P〈0.05）,ICR和昆明小鼠的直立次数也明显高于C57BL/6小鼠（P〈0.05）;悬尾实验C57BL/6小鼠的不动时间显著长于其他3种品系小鼠（P〈0.05）,但是4种品系小鼠在强迫游泳实验中的不动时间差异无显著性。结论 C57BL/6小鼠自发活动量低,对新奇环境的探索能力差,并且在急性应激刺激下容易造成行为绝望,因此C57BL/6小鼠可能适合作为急性应激抑郁模型动物。     

一株O型口蹄疫病毒在C57BL/6小鼠和原代细胞的传代及其全序的测定和分析

【目的】旨在成功建立FMDVC57BL/6小鼠的实验感染模型。【方法】采用体内和体外循环适应传代的方法,选取一株对C57BL/6小鼠不敏感FMDVO/HK/CHA/99MF4,将其在C57BL/6小鼠(体内)和胎猪肾原代细胞FPK (体外)进行多次循环适应传代。【结果】成功获得一株对C57BL/6小鼠敏感的FMDVO/HK/CHA/99MF4C5株。【结论】本研究成功建立了FMDV突变株感染C57BL/6小鼠的实验动物模型,为未来FMD疫苗效力的评估和致病性相关的研究奠定了基础。     

博来霉素诱导G57BL/6与ICR小鼠肺间质纤维化模型的比较

目的探讨C57BL/6与ICR小鼠在博来霉素(BLM)致肺纤维化过程中的种属差异。方法 8周龄雌性C57BL/6小鼠19只,ICR小鼠16只,分别经尾静脉一次性注射BLM150mg/kg,观察每组小鼠体重、生存率及肺组织病理改变。结果①C57BL/6与ICR小鼠最低体重分别发生在静脉注射处置后的7d和5d,最低体重分别为注射前的65.46%和73.21%,两组间无显著的统计学差异。②C57BL/6与ICR小鼠的生存率分别为36.84%和56.25%,两组间存在显著的统计学差异。③C57BL/6小鼠BLM注射后28d,在胸膜下及血管周围形成广泛、稳定的间质纤维化病理改变,而ICR小鼠肺组织未见明显纤维化形成。C57BL/6小鼠肺纤维化病理评分明显高于ICR小鼠(P0.001)。结论 BLM诱导的肺纤维化作用在C57BL/6与ICR小鼠间存在着明显的种属差异。C57BL/6小鼠较ICR小鼠更适于复制博来霉素诱导的肺纤维化动物模型。     

不同剂量MOG抗原免疫诱导小鼠自身免疫性脑脊髓炎模型的比较

目的比较不同剂量髓鞘少突胶质细胞糖蛋白(myelin oligodendrocyte glycoprotein,MOG35-55)免疫诱导C57BL/6小鼠实验性自身免疫性脑脊髓炎(experimental autoimmune encephalomyelitis,EAE)的作用。方法将C57BL/6小鼠分为正常组和三组不同剂量MOG35-55诱导的EAE模型组,共4组。模型组分别以每只200、100、50μg的MOG35-55与完全弗氏佐剂(complete Freund s adjuvant,CFA)混合的乳化抗原皮下注射免疫诱导EAE模型,正常组以生理盐水替代。观察不同剂量MOG35-55对C57BL/6小鼠体重、发病率以及神经功能评分等影响,同时取小鼠脑和脊髓,利用光镜和透射电镜观察小鼠病理组织学改变。结果三组不同剂量MOG35-55均能诱导EAE模型,发病率为100%,呈慢性单相病程,病理学观察发现小鼠脑和脊髓有炎性细胞浸润、脱髓鞘及轴突损伤等改变。但小剂量组在体重减轻、临床症状评分及病理学改变等方面均较中、大剂量组明显。结论用MOG35-5550μg剂量免疫诱导的C57BL/6小鼠EAE模型稳定,可在今后的研究中应用。     

发酵乳杆菌AR497改善DSS诱导的小鼠炎症性肠病

本实验主要探究发酵乳杆菌AR497对DSS诱导的小鼠炎症性肠病的影响。发酵乳杆菌AR497在低pH、高胆盐浓度、高渗透压等极端条件下仍具有良好的生长能力,对大部分抗生素敏感;在C57BL/6J小鼠中研究其对由葡聚糖硫酸钠(DSS)诱导的结肠炎的缓解作用,发酵乳杆菌AR497处理后抑制小鼠体重减少,降低疾病活动指数,上调紧密连接蛋白基因Claudin 3,ZO-1和E-cadherin 1的表达。实验结果表明发酵乳杆菌AR497具有优良的生物学特性并可通过保护肠道屏障从而缓解DSS诱导的结肠炎。     

Neuroimmunomodulative properties of dipeptidyl peptidase IV/CD26 in a TNBS-induced model of colitis in mice

Causal connections between dipeptidyl peptidase IV, also known as CD26 molecule (DPP IV/CD26) and inflammatory bowel disease (IBD) have been shown, but mechanisms of these interactions are unclear. Our hypothesis was that DPP IV/CD26 could affect the neuroimmune response during inflammatory events. Therefore, we aimed to evaluate its possible role and the relevance of the gut-brain axis in a model of IBD in mice. Trinitrobenzenesulfonic acid-induced (TNBS) colitis was induced in CD26-deficient (CD26(-/-) ) and wild-type (C57BL/6) mice. Pathohistological and histomorphometrical measurements were done. Concentrations and protein expressions of DPP IV/CD26 substrates neuropeptide Y (NPY) and vasoactive intestinal peptide (VIP) were determined. Concentrations of IL-6 and IL-10 were evaluated. Investigations were conducted at systemic and local levels. Acute inflammation induced increased serum NPY concentrations in both mice strains, more enhanced in CD26(-/-) mice. Increased NPY concentrations were found in colon and brain of C57BL/6 mice, while in CD26(-/-) animals only in colon. VIP and IL-6 serum and tissue concentrations were increased in both mice strains in acute inflammation, more pronouncedly in CD26(-/-) mice. IL-10 concentrations, after a decrease in serum of both mice strains, increased promptly in CD26(-/-) mice. Decreased IL-10 concentration was found in brain of C57BL/6 mice, while it was increased in colon of CD26(-/-) mice in acute inflammation. DPP IV/CD26 deficiency affects the neuroimmune response at systemic and local levels during colitis development and resolution in mice. Inflammatory changes in the colon reflected on investigated parameters in the brain, suggesting an important role of the gut-brain axis in IBD pathogenesis.     

Colonic microbiota alters host susceptibility to infectious colitis by modulating inflammation, redox status, and ion transporter gene expression

Individuals vary in their resistance to enteric infections. The role of the intestinal microbiota in altering susceptibility to enteric infection is relatively unknown. Previous studies have identified that C3H/HeOuJ mice suffer 100% mortality during Citrobacter rodentium-induced colitis, whereas C57BL/6 mice recover from infection. The basis for their differences in susceptibility is unclear and has been mainly attributed to differences in host genetics. This study investigated the role of the intestinal microbiota in altering susceptibility to C. rodentium-induced colitis. When the feces of C57BL/6 mice were gavaged into antibiotic treated C3H/HeOuJ mice, the C57BL/6 microflora led to a complete reversal in mortality patterns where 100% of the C3H/HeOuJ mice survived infection. This protection corresponded with reduced colonic pathology and less systemic pathogen load and was associated with increased inflammatory and redox responses with reduced epithelial cell death. C3H/HeOuJ mice are normally susceptible to infection-induced dehydration due to defective expression of colonic ion transporters such as Dra, CA IV, and CA I; expression of these genes was normalized when C3H/HeOuJ mice were colonized with the C57BL/6 microflora. Together, these data reveal that the colonic microbiota play a critical role in protecting against intestinal infection by inducing proinflammatory and prooxidant responses that control pathogen load as well as ion transporter gene expression previously shown to prevent fatal dehydration. Protection of mice from lethal colitis was associated with higher levels of bacteria from Bacteroidetes. This study reveals that the microbiota is sufficient to overcome inherent genetic susceptibility patterns in C3H/HeOuJ mice that cause mortality during C. rodentium infection.     

Acute colitis induced by dextran sulfate sodium progresses to chronicity in C57BL/6 but not in BALB/c mice: correlation between symptoms and inflammation

Exposure to dextran sulfate sodium (DSS) induces acute colitis, which is normally resolved after DSS removal. To study chronicity, mice are typically subjected to three to five cycles of weekly DSS exposures, each followed by a 1- to 2-wk rest period. Here, we describe a novel and convenient way of inducing chronic, progressive colitis by a single exposure to DSS. C57BL/6 mice exposed to DSS for 5 days developed acute colitis that progressed to severe chronic inflammation. The plasma haptoglobin levels remained high during the chronic phase, showing that the inflammation was active. Surprisingly, the mice regained their original weight along with the progression of colitis, and the only apparent symptom was loose feces. Histopathological changes 4 wk after DSS removal were dense infiltrates of mononuclear cells, irregular epithelial structure, and persistent deposits of collagen. A progressive production of the cytokines IL-1beta, IL-12 p70, and IL-17 correlated with the extensive cellular infiltration, whereas high IFN-gamma production was mainly found late in the chronic phase. Similar to C57BL/6 mice, BALB/c mice exposed to 5 days of DSS developed acute colitis as previously described. The acute colitis was accompanied by elevated plasma levels of haptoglobin and increased colonic levels of IL-1alpha/beta, IL-6, IL-18, and granulocyte colony-stimulating factor. However, soon after DSS removal, BALB/c mice recovered and were symptom free within 2 wk and completely recovered 4 wk after DSS removal in terms of histopathology, haptoglobin levels, and local cytokine production. In summary, these data stress the effect of genetic background on the outcome of DSS provocation. We believe that the present protocol to induce chronic colitis in C57BL/6 mice offers a robust model for validating future therapies for treatment of inflammatory bowel disease.     

Endothelin in human inflammatory bowel disease: comparison to rat trinitrobenzenesulphonic acid-induced colitis

There have been suggestions that endothelins (ET-1, ET-2, ET-3) are involved in the pathogenesis of human inflammatory bowel disease (IBD). Furthermore, the non-selective endothelin receptor antagonist, bosentan, ameliorates colonic inflammation in TNBS colitis in rats. However, no studies have measured the tissue expression and release of endothelins in human IBD in direct comparison to experimental TNBS colitis. Mucosal biopsies were obtained from 114 patients (42 Crohn's colitis, 35 ulcerative colitis and 37 normal) and compared to whole colonic segments from rats with TNBS colitis. ET-1/2 levels were reduced in human IBD but greatly increased in experimental TNBS colitis. RT-PCR indicated ET-2 was the predominant endothelin isoform in human IBD whereas ET-1 prevailed in the TNBS model. No associations were found between human IBD and tissue expression, content or release of ET-1/2. Our study shows, therefore, that unlike TNBS colitis in rats, in which ET-1/2 levels are greatly elevated and ET receptor antagonists are efficacious, there is no significant link between endothelins and human IBD.     

Roxadustat protect mice from DSS-induced colitis in vivo by up-regulation of TLR4

BackgroundThe incidence of inflammatory bowel disease (IBD) is growing in the population. At present, the etiology of inflammatory bowel disease remains unclear, and there is no effective and low-toxic therapeutic drug. The role of the PHD-HIF pathway in relieving DSS-induced colitis is gradually being explored.MethodsWild-type C57BL/6 mice were used as a model of DSS-induced colitis to explore the important role of Roxadustat in alleviating DSS-induced colitis. High-throughput RNA-Seq and qRT-PCR methods were used to screen and verify the key differential genes in the colon of mice between normal saline (NS) and Roxadustat groups.ResultsRoxadustat could alleviate DSS-induced colitis. Compared with the mice in the NS group, TLR4 were significantly up-regulated in the Roxadustat group. TLR4 KO mice were used to verify the role of TLR4 in the alleviation of DSS-induced colitis by Roxadustat.ConclusionRoxadustat has a repairing effect on DSS-induced colitis, and may alleviate DSS-induced colitis by targeting the TLR4 pathway and promote intestinal stem cell proliferation.     

Protection from radiation-induced colitis requires MHC class II antigen expression by cells of hemopoietic origin.

Ulcerative colitis, an inflammatory bowel disease, is believed to result from a breakdown of dominant tolerance mechanisms that normally control intestinal immunity. Although CD4+ T lymphocyte subpopulations and expression of MHC class II molecules have been shown to play a role in the pathogenesis of the disease, the nature of the responsible mechanisms remains unclear. In this paper we describe a novel mouse model for inflammatory bowel disease, radiation-induced colitis, that occurs with complete penetrance 6-8 wk postinduction. A combination of high dose gamma-irradiation and lack of MHC class II expression on cells of hemopoietic origin results in development of colitis in C57BL/6 mice. Because of its versatility (due to susceptibility of mice of the widely genetically manipulated C57BL/6 background), high reproducibility, and 100% penetrance, radiation-induced colitis will be a useful mouse model for colitis and a significant tool to study dominant immunological tolerance mechanisms. Moreover, our data imply that tolerization to enteric Ags requires MHC class II mediated presentation by APC of hemopoietic origin.     

Modulation of visceral hypersensitivity by glial cell line-derived neurotrophic factor family receptor α-3 in colorectal afferents

Irritable bowel syndrome is characterized by colorectal hypersensitivity and contributed to by sensitized mechanosensitive primary afferents and recruitment of mechanoinsensitive (silent) afferents. Neurotrophic factors are well known to orchestrate dynamic changes in the properties of sensory neurons. Although pain modulation by proteins in the glial cell line-derived neurotrophic factor (GDNF) family has been documented in various pathophysiological states, their role in colorectal hypersensitivity remains unexplored. Therefore, we investigated the involvement of the GDNF family receptor α-3 (GFRα3) signaling in visceral hypersensitivity by quantifying visceromotor responses (VMR) to colorectal distension before and after intracolonic treatment with 2,4,6-trinitrobenzene sulfonic acid (TNBS). Baseline responses to colorectal distension did not differ between C57BL/6 and GFRα3 knockout (KO) mice. Relative to intracolonic saline treatment, TNBS significantly enhanced the VMR to colorectal distension in C57BL/6 mice 2, 7, 10, and 14 days posttreatment, whereas TNBS-induced visceral hypersensitivity was significantly suppressed in GFRα3 KO mice. The proportion of GFRα3 immunopositive thoracolumbar and lumbosacral colorectal dorsal root ganglion neurons was significantly elevated 2 days after TNBS treatment. In single fiber recordings, responses to circumferential stretch of colorectal afferent endings in C57BL/6 mice were significantly increased (sensitized) after exposure to an inflammatory soup, whereas responses to stretch did not sensitize in GFRα3 KO mice. These findings suggest that enhanced GFRα3 signaling in visceral afferents may contribute to development of colorectal hypersensitivity.     

细胞粘附分子CHL1缺失对炎症性肠病的影响

目的：探讨细胞粘附分子CHL1缺失对炎症性肠病（IBD）的影响。方法：采用葡聚糖硫酸钠（DSS）建立CHL1（-/-）炎症性肠病小鼠模型,将10只C57/BL6为遗传背景的CHL1（+/+）型小鼠分为对照组、DSS模型组（n=5）;将10只C57/BL6为背景的CHL （-/-）型小鼠分为CHL1缺失组、CHL1缺失DSS模型组（n=5）。DSS模型组和CHL1缺失DSS模型组自主饮用7 d含1.5% DSS蒸馏水,随后改用蒸馏水饲喂2 d;对照组和CHL1缺失组连续饮用蒸馏水9 d,观察小鼠体重、血便、生存率及结肠组织长度的变化。结果：CHL1缺失DSS模型组小鼠在炎症性肠病的发生中便血明显,从应激的第7天开始,体重明显减轻,在第9天,CHL1缺失DSS模型组型小鼠死亡率明显增加;结肠长度明显缩短,损伤加重。结论：细胞粘附分子CHL1缺失加重炎症性肠病的发生。     

Menthacarin attenuates experimental colitis

BackgroundPeppermint oil and caraway oil are established remedies in gastroenterological medicine because of their spasmolytic/analgesic effects.PurposeWe investigated whether Menthacarin, a combination of both oils, exerted anti-inflammatory effects in a dextran sodium sulphate (DSS, 2%) murine model of colitis.Study Design and MethodsC57BL/6 mice were orally administered Menthacarin in doses of 10, 30, 60, and 120 µg/g body weight (BW), and control mice received 0.2% agar, 10 µl/g BW, during 8 days of DSS-induced colitis. Colitis was monitored by BW measurements and colonoscopies. Colons of euthanised mice were excised for histological staining and ELISA measurements of the cytokines TNFα, IL-6, IL-10, IL-1β, and TGF-β.ResultsMenthacarin-treated mice compared to controls showed improved macroscopical and microscopical parameters and lower BW loss during the course of colitis. Menthacarin changed the colonic cytokine profile towards a regulatory/anti-inflammatory phenotype.ConclusionMenthacarin attenuates experimental colitis and may be a promising add-on therapy for the treatment of IBD.